Ligand Pharmaceuticals reported 56.5 in PE Price to Earnings for its fiscal quarter ending in March of 2026.





Pe Change Date
Amgen 19.84 5.47 Mar/2026
Anika Therapeutics 47.54 27.2 Jun/2024
Baxter International 86 68.9 Dec/2025
Bristol-Myers Squibb 9.08 0.2 Mar/2026
Eli Lilly 40.27 0.06 Mar/2026
Enviri Corporation 121.21 92.59 Jun/2023
Gilead Sciences 17.7 2.07 Mar/2026
GlaxoSmithKline 14.87 3.72 Mar/2026
Glaxosmithkline 11.66 0.28 Dec/2025
Intrexon 7.54 221.44 Dec/2021
Ionis Pharmaceuticals 396.15 79.28 Sep/2022
Ligand Pharmaceuticals 56.5 26.8 Mar/2026
Merck 16.52 2.6 Mar/2026
Pacira 38.58 14.1 Mar/2026
Pfizer 9.32 5.16 Mar/2026
Rigel Pharmaceuticals 8.61 8.4 Mar/2025
Veracyte 24.89 20.41 Mar/2026